Protagonist Therapeutics: "Strong Buy" ICOTYDE FDA Approval And PN-881 Advancement

Protagonist Therapeutics (PTGX) maintains a "Strong Buy" rating, driven by FDA approval of ICOTYDE for moderate-to-severe plaque psoriasis and strong partnership economics. Company is advancing rusfertide for polycythemia vera, with FDA Priority Review decision expected August 2026 and substantial milestone and royalty potential from Takeda. Development pipeline includes oral IL-17 antagonist PN-881 for psoriasis and other inflammatory disorders, with phase 2b study initiation planned for Q1 2027.

11.08.2026

4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026

PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.

07.08.2026

Surging Earnings Estimates Signal Upside for Protagonist Therapeutics (PTGX) Stock

Protagonist Therapeutics (PTGX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

05.08.2026

Protagonist Therapeutics (PTGX) Beats Q2 Earnings Estimates

Protagonist Therapeutics (PTGX) came out with quarterly earnings of $2.29 per share, beating the Zacks Consensus Estimate of $2.11 per share. This compares to a loss of $0.55 per share a year ago.

04.08.2026

Protagonist Therapeutics Reports Granting of Inducement Awards

NEWARK, CA / ACCESS Newswire / August 4, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on July 31, 2026, it granted inducement awards to two recently hired employees in accordance with the terms of their employment offer letters. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.

Videos

No Data

There is no data to display

Upgrades / Downgrades

Ticker	Brokerage Firm	Ratings Change	Price Target	Date
PTGX	Goldman	Buy	undefined >> $186	August 10th 2026

Press releases

04.08.2026

Protagonist Therapeutics, Inc. (PTGX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Protagonist Therapeutics, Inc. (PTGX)

Protagonist Therapeutics: "Strong Buy" ICOTYDE FDA Approval And PN-881 Advancement

4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026

Surging Earnings Estimates Signal Upside for Protagonist Therapeutics (PTGX) Stock

Protagonist Therapeutics (PTGX) Beats Q2 Earnings Estimates

Protagonist Therapeutics Reports Granting of Inducement Awards

Videos

No Data

Upgrades / Downgrades

Press releases

Protagonist Therapeutics Reports Granting of Inducement Awards

Search stocks

Protagonist Therapeutics, Inc. (PTGX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Protagonist Therapeutics, Inc. (PTGX)

Protagonist Therapeutics: "Strong Buy" ICOTYDE FDA Approval And PN-881 Advancement

4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026

Surging Earnings Estimates Signal Upside for Protagonist Therapeutics (PTGX) Stock

Protagonist Therapeutics (PTGX) Beats Q2 Earnings Estimates

Protagonist Therapeutics Reports Granting of Inducement Awards

Videos

No Data

Upgrades / Downgrades

Press releases

Protagonist Therapeutics Reports Granting of Inducement Awards